The Motley Fool

Volpara CEO confident of strong finish to 2019

This morning medical software player Volpara Health Technologies Ltd (ASX: VHT) reported an operating cash loss of NZ$4.24 million on sales of NZ$4.89 million for the quarter ending September 30, 2019. The company flagged a ‘one off’ payroll timing adjustment for a blow out in staff costs that dragged the overall quarterly result lower. 

It also completed the acquisition of Seattle-based breast screening business MRS Systems in the prior quarter to distort comparisons to prior corresponding quarters.

Volpara reported annualised recurring revenue (ARR) including the MRS acquisition was NZ$15.7 million (US$10.3m) as at September 30 2019. The group is now selling software to assist in the detection of both breast and lung cancer. 

After a A$55 million capital raising in June 2019 the company has NZ$40.9 million cash on hand and is forecasting a cash outflow of NZ$8.97 million in the December quarter. 

The CEO, Ralph Higham, is confident of a big December quarter: “We’re very much looking forward to Q3 with the delivery of new integrated products at RSNA (Radiological Society of North America), our big trade show in Chicago; the publication of the DENSE results from the Netherlands after a 10-year randomised control trial using Volpara®DensityTM software; and a possible breast density announcement from the FDA (US Food and Drug Administration).”

Based on 218 million shares on issue Volpara is valued around $357 million based on a $1.64 share price. 

We can see why it was keen to get a capital raising away at a $1.50 per share back in June and the company’s share price is perhaps flying higher than its financial results. 

Others in the medtech space flying high include Pro Medicus Limited (ASX: PME) and Nanosonics Ltd (ASX: NAN).

Top 3 Dividend Shares To Buy For 2020

When Edward Vesely -- our resident dividend expert -- has a stock tip, it can pay to listen. With huge winners like Dicker Data (up 147%) and Collins Food (up 105%) under his belt, Edward is building an enviable following amongst investors that are planning for retirement.

In a brand new report, Edward has just revealed what he believes are the 3 best dividend stocks for income-hungry investors to buy now. All 3 stocks are paying growing fully franked dividends giving you the opportunity to combine capital appreciation with attractive dividend yields.

Best of all, Edward’s “Top 3 Dividend Shares To Buy For 2020” report is totally free to all Motley Fool readers.

Click here now to access this free report.

Tom Richardson owns shares of Pro Medicus Ltd and Dicker Data.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and recommends Pro Medicus Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Nanosonics Limited and VOLPARA FPO NZ. The Motley Fool Australia has recommended Nanosonics Limited, Pro Medicus Ltd., and VOLPARA FPO NZ. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.

CLICK HERE FOR YOUR FREE REPORT!